Obtaining Real-World Disease, Demographic Data on Myelofibrosis
Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about why data are limited in myelofibrosis.
In an interview with Pharmacy Times, Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute, spoke about why real-world disease and demographic factors are limited in the study of myelofibrosis. Komrokji presented at the 62nd American Society of Hematology Annual Meeting and Exposition on ‘To Treat or Not to Treat? Understanding Treatment Patterns in Patients with Lower-Risk Myelofibrosis at the Time of Enrollment in the MOST Study.’
